
- ONCOLOGY Vol 13 No 8
- Volume 13
- Issue 8
TRICARE Expands Cancer Clinical Trials Demonstration
TRICARE, the health plan for active duty military personnel (formerly known as CHAMPUS), expanded its cancer clinical trials demonstration so that beneficiaries could enter cancer prevention trials sponsored by the National Cancer Institute
TRICARE, the health plan for active duty military personnel (formerly known as CHAMPUS), expanded its cancer clinical trials demonstration so that beneficiaries could enter cancer prevention trials sponsored by the National Cancer Institute (NCI). The demonstration had previously been limited to cancer treatment trials. The expansion, effective in June, was somewhat of a last-ditch effort to entice more TRICARE beneficiaries into the demonstration so that TRICARE could obtain more data on which to base future decisions. Between January 1996 and August 1998, only 155 TRICARE beneficiaries enrolled in NCI trials, and those were almost exclusively for bone marrow transplants.
Of course, TRICARE has a much better record on covering patient costs of participating in cancer clinical trials than almost any other health plan. Sens. Jay Rockefeller (D-W. Va.) and Connie Mack (R-Fla.) have been trying for years to persuade Congress to pass a bill authorizing a Medicare demonstration that would ensure coverage of patient care costs. No bill has ever gotten out of a Senate committee.
Articles in this issue
almost 27 years ago
Klausner Commits to Increased Funding of Prostate Cancer Researchalmost 27 years ago
Study Confirms Value of Paclitaxel Plus Paraplatin in NSCLCalmost 27 years ago
City of Hope Receives $36 Million for State-of-the-Art Hospitalalmost 27 years ago
Peaceful Dyingalmost 27 years ago
Radiation Helps Prostate Cancer Patients Live Longer, Study Showsalmost 27 years ago
Innovative Clinical Trial for Patients With Advanced Pancreatic Canceralmost 27 years ago
Cord Blood to Be Used in Breast Cancer Studyalmost 27 years ago
Mounting Evidence for Postmastectomy Locoregional Radiation TherapyRelated Content




93 monarchE: Primary Overall Survival Results of Adjuvant Abemaciclib + Endocrine Therapy for HR+/HER2−, High-Risk, Early Breast Cancer
























































